Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease.

Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH.

Lancet Neurol. 2009 Oct;8(10):929-37. doi: 10.1016/S1474-4422(09)70225-X. Epub 2009 Aug 24. Review.

PMID:
19709931
2.

Validation of the freezing of gait questionnaire in patients with Parkinson's disease.

Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E.

Mov Disord. 2009 Apr 15;24(5):655-61. doi: 10.1002/mds.21745.

PMID:
19127595
3.

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.

Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators.

Lancet Neurol. 2007 Jun;6(6):513-20.

PMID:
17509486
4.

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group.

Ann Neurol. 2003 Jul;54(1):93-101.

PMID:
12838524
5.
6.

An early report of striatonigral degeneration.

Wenning GK, Jellinger KJ, Quinn NP, Poewe WH.

Mov Disord. 2000 Jan;15(1):159-62. No abstract available.

PMID:
10634258
7.

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S.

Neurology. 1999 Jul 22;53(2):364-70. Erratum in: Neurology 1999 Sep 22;53(5):1162.

PMID:
10430427
8.

The natural history of Parkinson's disease.

Poewe WH, Wenning GK.

Ann Neurol. 1998 Sep;44(3 Suppl 1):S1-9. Review.

PMID:
9749568
9.

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.

Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F.

Mov Disord. 1998 Jan;13(1):46-51.

PMID:
9452325
10.

Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.

Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F.

Mov Disord. 1998 Jan;13(1):39-45.

PMID:
9452324
11.

The natural history of Parkinson's disease.

Poewe WH, Wenning GK.

Neurology. 1996 Dec;47(6 Suppl 3):S146-52. Review.

PMID:
8959983
12.

Clinical aspects of motor fluctuations in Parkinson's disease.

Poewe WH.

Neurology. 1994 Jul;44(7 Suppl 6):S6-9. Review.

PMID:
8047260
13.

Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease.

Schelosky L, Benke T, Poewe WH.

J Neural Transm Suppl. 1991;33:125-32.

PMID:
1753241
14.

Dystonia in Parkinson's disease: clinical and pharmacological features.

Poewe WH, Lees AJ, Stern GM.

Ann Neurol. 1988 Jan;23(1):73-8.

PMID:
3345068
15.

Primary CNS lymphoma presenting as a choreic movement disorder followed by segmental dystonia.

Poewe WH, Kleedorfer B, Willeit J, Gerstenbrand F.

Mov Disord. 1988;3(4):320-5.

PMID:
3211177
16.

The pharmacology of foot dystonia in parkinsonism.

Poewe WH, Lees AJ.

Clin Neuropharmacol. 1987;10(1):47-56. Review. No abstract available.

PMID:
3545460
18.

Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study.

Poewe WH, Lees AJ, Stern GM.

Neurology. 1986 Nov;36(11):1528-30.

PMID:
3762973
19.

Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.

Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS.

Ann Neurol. 1986 Aug;20(2):258-62.

PMID:
3092728
20.

The centenary of Friederich H. Lewy 1885-1950.

Gibb WR, Poewe WH.

Neuropathol Appl Neurobiol. 1986 May-Jun;12(3):217-22. Review. No abstract available.

PMID:
3526168

Supplemental Content

Loading ...
Support Center